Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Horizon hikes Depomed offer to $2B in bid for ‘friendly’ deal talks

July 21, 2015
Life sciences
Don’t get Horizon Pharma wrong. It intends to pursue Depomed as an M&A target whether the California company likes it or not. But it would prefer for Depomed to like it–and in an effort to spur a “friendly, negotiated transaction,” it’s raising its bid.
 
Tuesday, the Irish pharma put forth a $33 per share proposal–up from its previous $29.25-per-share offer. The new bid represents a 60% premium to Depomed’s share price the day before Horizon took its intentions public, or about $1.97 billion. But that price is contingent on Depomed “rapidly entering into good faith discussions regarding a transaction,” Horizon CEO Timothy Walbert wrote in a letter to his target’s board.
 
On that front, Walbert said his company remains “surprised and disappointed” that Depomed hasn’t yet come to the bargaining table. Based on talks Horizon has had with shareholders on both sides, “it is clear that they and the investment community strongly support a combination of our two businesses,” he said in a statement.
 
For its part, Depomed so far hasn’t shown any signs that it’s up for a buyout. Last week, it adopted a poison pill plan that would be triggered if any person or group picks up an ownership stake larger than 10%.
 
But Depomed’s reticence won’t stop Horizon from moving forward, Walbert stressed: “Horizon remains committed to an acquisition of Depomed and we are prepared to consider all paths necessary to complete the transaction,” he said.
 
By Carly Helfand
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach